BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
Matthew J DurandShelby N HaderAlexa DerayunanNatalya ZinkevichJennifer J McIntoshAndreas M BeyerPublished in: Microcirculation (New York, N.Y. : 1994) (2020)
Incubating human arterioles with imatinib or nilotinib switches the mediator of FMD from vasoprotective nitric oxide to pro-inflammatory H2 O2 .